The landscape of oncology is currently undergoing a massive transformation as pharmaceutical giants race to develop best-in-class therapeutics for some of the world’s deadliest diseases. Because cancer remains the second leading cause of death globally, the sector has become a primary engine of growth within the life sciences industry. Investors are increasingly focusing on NASDAQ-listed firms that specialize in high-tech interventions like CAR-T cell therapies, genomics, and targeted vaccines to address prevalent forms of lung, breast, and prostate cancer.
Leading the pack in terms of market capitalization is Amgen, which leverages advanced human genetics to fight both solid tumors and blood cancers. The company has seen explosive success recently with its lung cancer therapy Imdelltra, which reported staggering year-over-year sales growth following expanded approvals in Europe and China. While Amgen navigates some regulatory hurdles regarding a subcutaneous version of its drug Blincyto, it continues to push forward with promising Phase 3 trials for prostate and colorectal cancer treatments.
Following closely behind is Gilead Sciences, a powerhouse known for diversifying its oncology pipeline through strategic acquisitions. Gilead has found significant momentum with Trodelvy, its breast cancer treatment that saw substantial sales growth thanks to new combined therapy approvals. Despite some setbacks in lung cancer trials, the company is gearing up for a potential December launch of anito-cel, an experimental therapy for multiple myeloma that could challenge existing market leaders.
Rounding out the top tier are international players like Sanofi and innovators like Regeneron Pharmaceuticals. Sanofi is making strides in patient convenience with its new subcutaneous delivery system for Sarclisa Escena, aiming to reduce infusion times across major global markets. Meanwhile, these companies continue to invest heavily in antibody-drug conjugates and genomic medicine platforms, ensuring that the battle against complex cancers remains at the forefront of biotechnological investment heading into 2027.